SynthesisNature communications2024
Predicting vaccine effectiveness for mpox.
Synthesis in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Toward Precision Vaccinology for Mpox: Rational Antigen Design, Next-Generation Platforms, and Immune Correlates of Protection.Tropical medicine and infectious disease · 2026Review
- Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence - a meeting report.Biologicals : journal of the International Association of Biological Standardization · 2026Article
- Article
- Measurement of the absolute mass concentration of antigen-specific serum IgG via quantitative Western blotting.Analytical biochemistry · 2026Article
- Mpox Outbreaks Beyond Historically Endemic Regions: A Clinical Review of Vaccination Strategies and Public Health Challenges.Dermatology (Basel, Switzerland) · 2026Review
- Mpox knowledge, attitudes toward Mpox vaccine and hesitancy for Mpox vaccination among teachers in Kenya.BMC public health · 2026Article
- First Complete Genome Sequencing of a Pigeonpox Virus Strain from Mainland China and Preliminary Evaluation of Its Attenuated Potential.Veterinary sciences · 2026Article
- Waning humoral immunity following monkeypox virus infection and vaccination, Canada, 2020 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Observational
- Post-pandemic changes in population immunity have reduced the likelihood of emergence of zoonotic coronaviruses.Nature communications · 2026Article
- Behavior change and infection induced immunity led to the decline of the 2022 Mpox outbreak in Berlin.Communications medicine · 2026Article
- Comparative humoral profiles in mpox cases, survivors, and vaccinated individuals reveal correlates of protection against MPXV.Cell reports. Medicine · 2025Article
- Mpox: Global epidemic situation and countermeasures.Virulence · 2025Review
- Article
- Optimal deployment of limited vaccine supplies to control mpox outbreaks.NPJ vaccines · 2025Article
- Review
- Comparative analysis of Mpox clades: epidemiology, transmission dynamics, and detection strategies.BMC infectious diseases · 2025Review
- Antibody Responses are Sustained 2 Years Post-Mpox Infection but not Following Modified Vaccinia Ankara-Bavarian Nordic Vaccination.Open forum infectious diseases · 2025Article
- Immune Response to MVA-BN Vaccination for Mpox: Current Evidence and Future Directions.Vaccines · 2025Review
- Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model.Nature communications · 2025Article
- Cost-effectiveness of vaccination strategies to control future mpox outbreaks in England: a modelling study.The Lancet regional health. Europe · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Modified Vaccinia Ankara vaccine developed by Bavarian Nordic (MVA-BN) was widely deployed to prevent mpox during the 2022 global outbreak. This vaccine was initially approved for mpox based on its reported immunogenicity (from phase I/II trials) and effectiveness in animal models, rather than evidence of clinical efficacy. However, no validated correlate of protection after vaccination has been identified. Here we performed a systematic search and meta-analysis of the available data to test whether vaccinia-binding ELISA endpoint titer is predictive of vaccine effectiveness against mpox. We observe a significant correlation between vaccine effectiveness and vaccinia-binding antibody titers, consistent with the existing assumption that antibody levels may be a correlate of protection. Combining this data with analysis of antibody kinetics after vaccination, we predict the durability of protection after vaccination and the impact of dose spacing. We find that delaying the second dose of MVA-BN vaccination will provide more durable protection and may be optimal in an outbreak with limited vaccine stock. Although further work is required to validate this correlate, this study provides a quantitative evidence-based approach for using antibody measurements to predict the effectiveness of mpox vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.